---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020847"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:37:41.831447+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics Q1 net loss $44.2M; on track for initial trial data H2 2023

## Summary
- Net loss $44.2M ($0.78/share) vs $35.6M ($0.69) in Q1 2022.
- Cash $238.2M at March 31; raised $24.2M via ATM after quarter; funds through 2024.
- R&D expenses $37.5M, up from $28.2M YoY.
- Enrollment continues in ACHIEVE (DM1) and DELIVER (DMD) trials; initial data expected H2 2023.
- DYNE-251 granted orphan drug and rare pediatric disease designations by FDA in March 2023.

## SEC filing metadata
- accession: 0000950170-23-020847
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017023020847/0000950170-23-020847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017023020847/dyn-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020847
- JSON: https://secwatch.observer/filing/0000950170-23-020847.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020847.txt

## Key facts
- Earnings Releases
  Dyne Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share., EPS $0.78 per basic and diluted share.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share.
  - EPS: $0.78 per basic and diluted share
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017023020847/0000950170-23-020847-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.